CORRECTING and REPLACING RMS Launches New Products and Models on RMS Risk Intelligence, the Unified Cloud Platform for Global Risk
Please replace the release issued May 4, 2020, with the following corrected version due to multiple revisions.
The corrected release reads:
RMS LAUNCHES NEW PRODUCTS AND MODELS ON RMS RISK INTELLIGENCE, THE UNIFIED CLOUD PLATFORM FOR GLOBAL RISK
Latest product releases include Risk Modeler 2.0, new and updated HD Models and intelligent applications purpose-built for navigating the growing risk landscape
As the world is changing in profound ways, so is risk. Climate change, pandemic events, and cyberattacks are threats we all now have to consider in new and innovative ways. With better understanding of risks, better decisions can be made, enabling better risk management end-to-end. Today, at the opening of its annual Exceedance conference, RMS , the world’s leading catastrophe risk solutions company, announced significant new model and product releases and updates for RMS Risk Intelligence™ (RI).
RMS Risk Intelligence (RI), first launched in May 2019, is an open, modular, unified, and reliable cloud platform that enables advanced modeling, deeper risk insights and analytics. Leveraging a cloud-native architecture, RI delivers higher performance and scale. With the RMS Risk Intelligence platform, there is no hardware or software to maintain, focused on reducing cost of ownership. The platform enables (re)insurers, the capital market, governments, and other organizations to efficiently operate and manage all their RMS risk models in the cloud, with an intuitive user experience, integrated with advanced risk analytics. RI is compliant with all industry recognized best-in-class security requirements such as GDPR, ISO27001, C5 and SOC2.
This week, during the virtual Exceedance 2020 conference, RMS will demonstrate significant advancements on RMS Risk Intelligence.
Risk Modeler 2.0
Risk Modeler 2.0™ is a break-through product release at RMS, running on RMS Risk Intelligence. Risk Modeler 2.0 provides advanced portfolio and account risk analyses leveraging RMS models and is designed to meet the complex needs of risk analysts and cat modelers. The latest version of the Risk Modeler product enables real-time risk analytics and unified, high performance execution of RiskLink® models and HD Models. It can also be easily integrated with on-premises modeling and other on-premises applications as well as other cloud applications through open APIs, giving customers maximum flexibility and choice. Risk Modeler 2.0 offers an all-in-one RiskLink and RiskBrowser experience, with familiar features along with an enhanced, intuitive user interface that streamlines workflows to reduce the time and steps it takes to complete complex analyses. Risk Modeler 2.0 is a unified modeling and analytics solution for an entire organization to run portfolio and account modeling workflows, promoting real-time risk insights.
Risk Modeler 2.0 provides:
- Global risk model coverage in North America, Europe, and Asia, with RiskLink versions 18.0 and 18.1 of core models, HD Models and specialty models
- Future-proof architecture for model engines that unify execution of RiskLink and HD Models under one roof
- Faster model execution. For some of the most popular RiskLink Models such as North Atlantic Hurricane, North America Earthquake, Europe Windstorm and North America Winterstorm, plus others that run four to six times faster on a one million location portfolio
- Simplified integration with existing systems with support for a rich set of data formats, from Exposure Data Module (EDM), Results Data Module (RDM), event loss tables (ELT) to period loss tables (PLT), and year loss tables (YLT)
- Zero-downtime upgrades and faster access to models with side-by-side model versions in one application
- Intuitive and familiar workflows including for RiskLink and RiskBrowser users
- Simplified usability, with batch processing of multiple steps such as the data upload process, now reduced to one-step
- API integration with third-party tools and in-house applications to enable a fully automated modeling end-to-end process, e.g., importing exposures, running geocoding and hazard lookup services
Risk Modeler 2.0 is available to customers in preview today and will be generally available with RiskLink models, with initial HD models in preview, by June 2020.
Risk Modeler with New HD Models
RMS High Definition Models are the next generation of risk modeling, delivering greater analysis and granularity than ever before. RMS HD Models have now all undergone a significant upgrade as they transitioned to the Risk Modeler application, which gives them greater flexibility and computational strength. The following models are in addition to the US Flood and US Wildfire HD Models that have been available through Risk Modeler’s earlier version:
- Updated Europe Inland Flood Model suite that covers 18 river basins and over 8,000 catchments across 15 countries in Europe
- Updated Japan Earthquake and Tsunami and New Zealand Earthquake models that both include sub-peril coverage for tsunami, fire-following, liquefaction and landslides
- Updated Japan Typhoon and Flood Model that incorporates the most recent events such as Typhoons Jebi and Hagibis
- Europe Severe Convective Storm Models, a brand new model suite that covers 17 countries with large pan-European event sets and is fully integrated with our Europe Windstorm Model.
All these HD Models are available today, and will be generally available between June and September 2020 in the Risk Modeler 2.0 application. Customers can evaluate and validate these models even earlier with the preview program for Risk Modeler, or through Analytical Services. Customers can access the Europe Inland Flood and US Wildfire Models starting in June on Risk Modeler 2.0, followed by Europe Severe Convective Storm, Japan Typhoon, Japan Earthquake and New Zealand Earthquake Models coming onto Risk Modeler 2.0 shortly after. All HD models will be generally available on the new Risk Modeler 2.0 by September 2020.
Analytical Application Suite
RMS Risk Intelligence also offers a new suite of advanced applications that are tailored for specific portfolio management and underwriting tasks. These include:
– This new application ensures portfolio managers gain deeper insights into their books with millions of locations, enabling easy discovery of hotspots, diversification and re-balancing their portfolio. The ExposureIQ application provides real-time exposure information combined with wind forecasting events and footprints from RMS Event Response to help gain a quicker assessment of potential losses before, during and after an event. Customers may gain advanced preview access to the Exposure IQ application in June and it will be generally available Sept 2020.
- Next versions of SiteIQ™ and Location Intelligence APIs -Rigorous catastrophe peril risk assessment can now be done in seconds, early in the underwriting process. The RMS SiteIQ and Location Intelligence APIs have been enhanced in these latest versions to provide fast and easy access to over 100 trillion data points and can now deliver over 200 data points per location in some regions, with current (and expanding) coverage of over 70+ countries.
- TreatyIQ™ - Harnessing a massively scalable roll-up engine, a trusted financial model, and flexible contract languages, the TreatyIQ application enables property treaty underwriters to achieve greater return on capacity with pricing and portfolio roll-up analytics. The Treaty IQ application will be available in preview in Q3 2020 and will be generally available in Q4.
Cihan Biyikoglu, Executive Vice President, Product, at RMS, said: “The significant advancements that the RMS team has made across all our products, HD Models, and especially Risk Modeler have been possible through collaboration with more than 400 RMS customers this past year. The Risk Intelligence unified cloud platform, through its innovative use of the risk data lake, the Risk Data Open Standard (RDOS), unified modeling and IQ applications - securely brings greater scale, capabilities and risk insights to the market. I am also excited about what the future holds in terms of new products and technologies. Further developments of the machine learning and artificial intelligence tools used by RMS will continue to open greater opportunities.”
Karen White, Chief Executive Officer at RMS said, “Risk Intelligence is the world’s first comprehensive global risk platform. The complexity and connectedness of risks continually confront us - we are all experiencing the crisis of COVID-19, along with the persistent crises of climate change, extreme weather and growing cyber threats. Facing all this, our industry needs a modern risk platform that takes advantage of all manner of data, modeling and analytics, in a way that is fast, integrated, and leverages technology in new ways for better insights and outcomes. RMS promised innovation, and with Risk Modeler 2.0 and the IQ applications, we have delivered – with an integrated platform for modeling risk in the cloud at the scale and speed required to take on the future of risk.”
Notes to editors:
Risk Management Solutions, Inc. (RMS) helps insurers, financial markets, corporations, and public agencies evaluate and manage global risk from natural and man-made catastrophes, including hurricanes, earthquakes, floods, climate change, cyber, and pandemics.
RMS leads the catastrophe risk industry that we helped to pioneer by marrying data and advanced model science with leading-edge technology. Leaders across multiple industries can address the risks of tomorrow through RMS Risk Intelligence™, our open, real-time exposure and risk management platform, enabling them to tap into RMS HD models, rich data layers, intuitive applications and APIs that simply integrate into existing enterprise systems.
RMS is a trusted solutions partner enabling effective risk management for better business decision making across underwriting, risk selection, mitigation, and portfolio management.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis129.5.2020 14:38:00 EEST | Press release
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond IPF.1 The opinion is based on the positive results of the INBUILD® phase III trial, the first study to evaluate adults with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behaviour.2 This follows the FDA’s and Health Canada’s approval of nintedanib as the first treatment for the same patient population.3,4 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.5 People living with fibrosing ILD can develop a progressive phenotype, leading to lung functio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom